Tags: Allergies | ALLTOP | ALLWWCUR | AMFEAT | APSY | BBPROFILE | BGOVBILLGO

Mylan Expands EpiPen Recall to Devices Distributed in US

Image: Mylan Expands EpiPen Recall to Devices Distributed in US
(Copyright Getty Images)

Sunday, 02 Apr 2017 08:41 PM

Mylan NV said it was expanding a recall of its EpiPen allergy injection to some lots of the device that have been distributed in the U.S., after defects were found that could keep the injectors from working in an emergency.

Mylcan called the defect “extremely rare,” and is recalling 13 lots of the pens. The company said it will replace pens from the recalled lots at no cost, and that people should keep the ones they have until they get their replacements.

“The recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution,” the drugmaker said in a statement Friday. EpiPen is licensed by Mylan, and the pens are manufactured by Meridian Medical Technologies, a unit of Pfizer Inc.

Nina Devlin, a Mylan spokeswoman, didn’t immediately respond to a request for comment.

EpiPen is one of Mylan’s biggest products, making up the backbone of its specialty drugs division. The company has faced criticism over the drug’s cost. EpiPen’s wholesale price has jumped six-fold since Mylan acquired its marketing rights in 2007 and it now lists for about $600 for a two-pack. Mylan also sells a generic version of EpiPen for $300.

The injection is used to counteract dangerous allergic reactions, such as those from bee stings or food allergies.

© Copyright 2017 Bloomberg News. All rights reserved.

   
1Like our page
2Share
Health-News
Mylan said it was expanding a recall of its EpiPen allergy injection to some lots of the device that have been distributed in the U.S., after defects were found that could keep the injectors from working in an emergency.
ALLTOP, ALLWWCUR, AMFEAT, APSY, BBPROFILE, BGOVBILLGO, BGOVCODES, BIZNEWS, BNALL, BNCOPY, BNCOPY2, BNSTAFF, BNTEAMS, BONDWIRES, BTX, BUSINESS, CMDGLOMAC, CMDKEY, COEVNT, CONSAFETY, COS, CPNYCNT1, DEVECO, DRG, EQUITYKEY, ESG, ESGCONTROV, ESGRES, ESGSOC, FINNEWS, G10MEMB, G7MEMB, GENCURZ3, GENTOP, GENTOPZ3, GLOBFEAT, GLOMACBB, HEA, HEACUR, HEACURZ2, HEATOP, HEATOPZ2, HLNOVEL, HLNOVELTY9, INDUSTRIES, INTERNAL, MAJOR, METALKEY, MISC, MSCINAMER, MSCIWORLD, NEGATIVE, NORTHAM, NOVEL, NOVELTY9, NRGKEY, NYX, OILKEY, ONWEB, ORIGINAL, PA, PADD1, PADDIST, READ, READ25, READ50, RECALL, SPREGIONS, SRCRANK1, STFILT241, STFILT266, TIMECO, TIMENI, TOP, TOPBIZMKT, US, USBNX, USHEALTH, USMA, USTOP, WEBELIG, WEBLIFESTY, WORLD, WWCUR, WWCURZ3, WWTOP, WWTOPAM, WWTOPBIZ, WWTOPFEAT, WWTOPGLOB, WWTOPZ3
217
2017-41-02
Sunday, 02 Apr 2017 08:41 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved